Altered miR-21, miRNA-148a Expression in Relation to KRAS Mutation Status as Indicator of Adenoma-Carcinoma Transitional Pattern in Colorectal Adenoma and Carcinoma Lesions

  • Somayeh Igder
  • Javad Mohammadiasl
  • Pooneh MokarramEmail author
Original Article


Sporadic colorectal cancer (CRC) is a fatal disease, mostly known as the silent killer, due to the fact that this disease is asymptomatic before diagnosis in advanced stage. Screening and the early detection of CRC and colorectal adenoma (CRA) by non-aggressive molecular biomarkers’ signature is useful for improvement of survival rate in CRC patients. To achieve such a goal, a better understanding of distinct molecular abnormalities as candidate biomarkers in CRC development is crucial. In this study, seventy-five archived FFPE CRC samples, including colorectal adenocarcinoma, adenomatous polyps (adenoma), and adjacent non-neoplastic mucosa were collected for the investigation by Sanger sequencing at the DNA level and by real-time PCR at the RNA level. The results of the KRAS mutational analysis have shown that the majority of somatic mutations in the KRAS affect only one codon, mainly codon 12(p.G12D) with low frequency in adenomas (13.3%) versus CRCs (36%). The results of dysregulated epigenetic changes of miR-21 clearly showed upregulation of expression in colorectal adenocarcinoma, compared to non-neoplastic mucosa, in colorectal adenoma vs non-neoplastic mucosa: (p < 0.001) and in CRC versus adenoma (p < 0.001); while miR-148a expression were significantly downregulated in CRC, compared to non-neoplastic mucosa, in colorectal adenoma vs non-neoplastic mucosa, and in adenoma vs CRC (p < 0.001). Our findings support the important role of miR-21 in stages I–II of CRC, and the KRAS G12D mutant, and differential miR-148a expression, in advanced stages of CRC.


Sporadic CRC miR-21 miR-148a The KRAS G12D mutant CRC development 



We thank our colleagues at the Department of Gastrointestinal Surgery and Institute of Digestive Surgery for providing tissue samples and pathological records. We would like to thank all colleagues who performed research in the field of microRNA and colorectal cancer. This study was financially supported by the Shiraz University of Medical Sciences [with Grant Number 94-01-01-10626]

Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflict of interest.

Supplementary material

10528_2019_9918_MOESM1_ESM.docx (22 kb)
Supplementary file1 (DOCX 22 kb)
10528_2019_9918_MOESM2_ESM.docx (14 kb)
Supplementary file2 (DOCX 13 kb)


  1. Armaghany T, Wilson JD, Chu Q, Mills G (2012) Genetic alterations in colorectal cancer. GCR 5(1):19Google Scholar
  2. Baltruskeviciene ED et al (2017) Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding. BMC Cancer 17(1):607. PubMedCentralGoogle Scholar
  3. Boutin AT et al (2017) Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev. PubMedCentralGoogle Scholar
  4. Bullock M et al (2013) Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis 4(6):e684. PubMedCentralGoogle Scholar
  5. Chuang T P et al. (2016). Over-expression of AURKA, SKA3 and DSN1 contributes to colorectal adenoma to carcinoma progression. Oncotarget 7(29): 45803. 9960
  6. Colussi D, Brandi G, Bazzoli F, Ricciardiello L (2013) Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 14(8):16365–16385. PubMedCentralGoogle Scholar
  7. Enquist IB et al (2014) Lymph node-independent liver metastasis in a model of metastatic colorectal cancer. Nat Commun 5:3530. Google Scholar
  8. Eslamizadeh S et al (2018) The Role of MicroRNA Signature as Diagnostic Biomarkers in Different Clinical Stages of Colorectal Cancer. Cell J (Yakhteh) 20:220–230. Google Scholar
  9. Grady WM, Carethers JM (2008) Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135(4):1079–1099. PubMedCentralGoogle Scholar
  10. Han D et al (2017) Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology 66(4):1151–1164. Google Scholar
  11. Hibino Y et al (2015) Significance of miR-148a in colorectal neoplasia: downregulation of miR-148a contributes to the carcinogenesis and cell invasion of colorectal cancer. Pathobiology 82(5):233–241. Google Scholar
  12. Knickelbein K, Zhang L (2015) Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis 2(1):4–12. Google Scholar
  13. Konda K et al (2014) Distinct molecular features of different macroscopic subtypes of colorectal neoplasms. PLoS ONE 9(8):e103822. PubMedCentralGoogle Scholar
  14. Lee KS et al (2016) Stromal expression of microRNA-21 in advanced colorectal cancer patients with distant metastases. J Pathol Transl Med 50(4):270. PubMedCentralGoogle Scholar
  15. Li W et al (2015) Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer 15(1):340. PubMedCentralGoogle Scholar
  16. Lionis C, Petelos E (2011) Early detection of colorectal cancer: barriers to screening in the primary care setting, Oxford University Press. Family Pract 28:589–591.
  17. Liu X, Jakubowski M, Hunt JL (2011) KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol 135(2):245–252. Google Scholar
  18. Liu X et al (2018) Synthetic circular RNA functions as a miR-21 sponge to suppress gastric carcinoma cell proliferation. Mol Ther Nucleic Acids 13:312–321. PubMedCentralGoogle Scholar
  19. Lorentzen JA et al (2016) Oncogene mutations in colorectal polyps identified in the Norwegian colorectal cancer prevention (NORCCAP) screening study. Clin Med Insights 9:S40143. Google Scholar
  20. Margetis N, Kouloukoussa M, Pavlou K, Vrakas S, Mariolis-Sapsakos T (2017) K-ras mutations as the earliest driving force in a subset of colorectal carcinomas. Vivo 31(4):527–542. Google Scholar
  21. Nielsen BS et al (2011) High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metast 28(1):27–38. Google Scholar
  22. Palmirotta R et al (2011) Concurrent mutation in exons 1 and 2 of the K-ras oncogene in colorectal cancer. Folia Histochem Cytobiol 49(4):729–733. Google Scholar
  23. Palomba G et al (2016) Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. Oncol Lett 12(2):1415–1421. PubMedCentralGoogle Scholar
  24. Payandeh M et al (2017) The prevalence of KRAS mutation in colorectal cancer patients in Iranian population: a systematic review and meta-analysis study. Biomed Res Therapy 4(10):1693–1704. Google Scholar
  25. Peng Q et al (2017) The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget 8(27):44893. PubMedCentralGoogle Scholar
  26. Price C, Chen J (2014) MicroRNAs in cancer biology and therapy: current status and perspectives. Genes Dis 1(1):53–63. PubMedCentralGoogle Scholar
  27. Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K (2012) Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-1, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12(1):505. PubMedCentralGoogle Scholar
  28. Soto Y et al (2016) Molecular evidence of high-risk human papillomavirus infection in colorectal tumours from Cuban patients. Memórias do Instituto Oswaldo Cruz 111(12):731–736. PubMedCentralGoogle Scholar
  29. Sun G et al (2016) Signature miRNAs in colorectal cancers were revealed using a bias reduction small RNA deep sequencing protocol. Oncotarget 7(4):3857. Google Scholar
  30. Takahashi M et al (2012) The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PloS ONE 7(10):e46684. PubMedCentralGoogle Scholar
  31. Tan C, Du X (2012) KRAS mutation testing in metastatic colorectal cancer. WJG 18(37):5171. Google Scholar
  32. Ulintz PJ, Greenson JK, Wu R, Fearon ER, Hardiman KM (2018) Lymph node metastases in colon cancer are polyclonal. Clin Cancer Res 24(9):2214–2224. Google Scholar
  33. Uratani R et al (2016) Diagnostic potential of cell-free and exosomal microRNAs in the identification of patients with high-risk colorectal adenomas. PloS ONE 11(10):e0160722. PubMedCentralGoogle Scholar
  34. Wu Y et al (2017) MicroRNA-21 (Mir-21) promotes cell growth and invasion by repressing tumor suppressor PTEN in colorectal cancer. Cell Physiol Biochem 43(3):945–958. Google Scholar
  35. Yamagishi H, Kuroda H, Imai Y, Hiraishi H (2016) Molecular pathogenesis of sporadic colorectal cancers. Chin J Cancer 35(1):4. PubMedCentralGoogle Scholar
  36. Ye JX et al (2015) KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. WJG 21:1595. Google Scholar
  37. Yuan H et al (2017) Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis. Oncotarget 8(28):46565. PubMedCentralGoogle Scholar
  38. Zauber P, Marotta S, Sabbath-Solitare M (2013) KRAS gene mutations are more common in colorectal villous adenomas and in situ carcinomas than in carcinomas. Int J Mol Epidemiol Genetics 4(1):1Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Biochemistry, School of MedicineShiraz University of Medical SciencesShirazIran
  2. 2.Department of Medical Genetics, School of MedicineAhvaz Jundishapur University of Medical SciencesAhvazIran
  3. 3.Colorectal Cancer Research Center and Department of BiochemistryShiraz University of Medical SciencesShirazIran

Personalised recommendations